Well known global digital healthcare journal Insights Care is honored to feature Predictive Oncology under the leadership of Raymond Vennare, Chief Executive Officer and Chairman of the Board, among the innovative companies pioneering drug discovery using AI solutions.
One of the firms that is leveraging the capabilities of AI to create new solutions for cancer treatment includes Predictive Oncology. It is a science-driven firm that deals with engaging in the application of artificial intelligence and machine learning with the aim of accelerating research, discovery, and development of oncology drugs.
Predictive Oncology’s machine learning-based drug discovery Patient-focused Discovery by Active Learning platform (PEDAL) marries scientific rigor and machine learning to leverage one of the world’s largest privately owned biobanks of tumor samples in an attempt to overcome the shortcomings of clinical trials and improve the chances of success.
Another great amenity they have that places them at the top of the other drug discovery companies is the fact that they have alliances with several biopharmaceutical companies. This allows them to screen therapeutic prospects against a heterogenous biobank of over 150K tumor samples, leading to more thoughtful drug/tumor type pairings.
The Chief Executive Officer and Board Chair, Raymond Vennare, is leading these Predictive Oncology activities. He has worked in the biotechnology sector for over thirty years. Personal bereavement due to cancer among his immediate family members has driven him to work towards the application of effective solutions in cancer treatment.
Raymond and Predictive Oncology’s team have the fight against cancer in both a personal and professional sense; and through their shared vision of ‘bringing hope to cancer patients,’ they are revolutionizing the field of oncology drug discovery.
He also opines that Predictive Oncology is at the point of tipping for oncology drug discovery and Predictive Oncology is at the forefront of driving that change. He owes it to Predictive Oncology’s amazing team of scientists, doctors, computational biologists, software engineers, and lab technicians, who have made it their goal to help the industry accelerate drug discovery and create more effective cancer treatments.
It is this synergy of passion and knowledge, facilitated and aided by the proprietary technology of the company itself, that is catapulting Predictive Oncology onto a path of innovation that will, in the next years, change the paradigm for oncology drug development. Their PEDAL platform integrates patient heterogeneity sooner than was previously conceivable in the process of drug discovery, essentially peering five years down the road in drug development before clinical trials.
Read Also : Fredrick Redd | Visionary Leadership in Business Innovation
